Beam Therapeutics Stock Forecast
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BEAM analyst consensus
Consensus (15 analysts)
strong_buy
Avg. price target
$52.15+110.54%
- Strong buy 1
- Buy 12
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 15 Wall Street analysts covering Beam Therapeutics (2026-10-07), 13 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $52.15, with a high estimate of $80.00 and a low estimate of $26.00. The average target implies upside of 110.5% from the current price of $24.77.
The spread between the highest and lowest targets is 207.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BEAM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 12 | 80% |
| Hold | 2 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $26.00 | +4.97% |
| Average target | $52.15 | +110.54% |
| High target | $80.00 | +222.97% |